Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Predictive Oncology Inc. (NASDAQ:POAI), a micro-cap company with a market capitalization of $7 million, announced that on Tuesday it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC, stating that the company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The stock has struggled recently, declining over 41% in the past six months, according to InvestingPro data. The notice was issued after the company’s common stock closed below $1.00 per share for 30 consecutive business days, as required under Nasdaq Marketplace Rule 5550(a)(2).
According to the company’s statement, the notification does not have an immediate effect on the listing of its common stock. Predictive Oncology has been granted a 180-calendar-day period, until January 5, 2026, to regain compliance. To meet the requirement, the company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the deadline.
If Predictive Oncology does not regain compliance by January 5, 2026, it may be eligible for an additional compliance period if it meets other initial listing standards for the Nasdaq Capital Market, except for the bid price requirement. The company would need to notify Nasdaq in writing of its intention to cure the deficiency, which could include implementing a reverse stock split. If it appears that the company will not be able to resolve the deficiency, or if it is otherwise ineligible, Nasdaq staff may notify the company that its securities are subject to delisting. In such a case, Predictive Oncology would have the right to appeal the determination, although there is no assurance that an appeal would be granted.
The company stated it is actively monitoring its stock price and considering available options to resolve the deficiency and regain compliance.
This information is based on a press release statement included in Predictive Oncology’s recent SEC filing.
In other recent news, Predictive Oncology Inc. has entered into a standby equity purchase agreement with YA II PN, LTD, managed by Yorkville Advisors Global, LP. This agreement allows Predictive Oncology to sell up to $10 million worth of its common stock, providing a flexible funding source for its drug discovery initiatives and business development opportunities. The company maintains discretion over the timing and amount of stock sales, with no obligations to use the full amount. Additionally, Predictive Oncology is preparing to defend itself against Renovaro, Inc. in a legal dispute scheduled for trial in November 2025, as determined by the Delaware Court of Chancery.
In a separate development, Predictive Oncology announced advancements in its AI-enabled drug discovery capabilities. The company has developed predictive tumor response models for 21 molecules that previously lacked response data, leveraging its biobank of over 150,000 tumor samples. This progress underscores the potential of AI in early drug discovery, particularly when combined with empirical validation. The company’s PEDAL platform, which predicts tumor responses with 92% accuracy, supports these efforts by guiding drug and tumor type selections for further testing. These recent developments highlight Predictive Oncology’s ongoing commitment to advancing AI-driven solutions in cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.